top of page

Biopharma Pulse - 3/28 - 4/1 Week in Review

  • Writer: BPIQ
    BPIQ
  • Apr 1, 2022
  • 2 min read

As March concluded this week, we review moves from smid-cap biopharma companies during this past week as well as March as a whole. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.


Table 1. BPIQ company weekly/monthly moves and YTD moves




Highlights for the week of 3/28-4/1


Biggest positive move

  • $LGVN +131.6% Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Associatio


Biggest negative move

  • $AKBA -72.3% Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients


Additional big moves

  • $IGMS +96.7% Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology, and Inflammation Targets.

  • $JAGX +32.2% Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets

  • $CLVS +22.4% Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival In First-Line Maintenance Treatment In Women With Ovarian Cancer Regardless Of Their Biomarker Status In Phase 3 ATHENA-MONO Trial

  • $IMGN +11.7% ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer.

  • $VSTM +10.9% Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors.

  • $VBIV +10.1% VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults.

  • $ELOX +10.0% Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

  • $OTLK -10.6% Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

  • $SPRO -18.28% Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update

  • $LPCN -20.3% LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™.

  • $SLNO -22.8% Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering.

  • $IFRX -23.4% InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

  • $SLS -37.87% SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering





Highlights for March 2022


Biggest positive move

  • $ICVX +59.64% Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Biggest negative move

  • $AKBA -72.3% Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients


Highlights for next week

  • $BTAI PDUFA

  • $IMRA Interim update

  • AACR begins on April 8





See our Big Movers post to learn about upcoming April Movers and PDUFAs after subscribing. Learn more here.



 
 
 

Comments

bottom of page